Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Medical Solutions LSE:AMS London Ordinary Share GB0004536594 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.50p -2.02% 316.00p 315.00p 316.00p 323.50p 316.00p 321.50p 139,390 16:16:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 82.6 19.1 7.5 42.2 671.83

Advanced Medical Solutions Share Discussion Threads

Showing 7001 to 7024 of 7025 messages
Chat Pages: 281  280  279  278  277  276  275  274  273  272  271  270  Older
DateSubjectAuthorDiscuss
18/1/2018
16:13
Next leg up?
volsung
16/1/2018
11:10
Easy to forget it was 200p at the start of 2017!
wetdream
16/1/2018
11:08
Seemed to be a series of five-figure 'O' trade sells yesterday that took the share price down below 300p. Normal service resumed today however. ;-)
wetdream
10/1/2018
20:52
Could be a Head and shoulders pattern. Target price is around historical support 295-298. Potential turn date 26/01/2018.
bamboo2
10/1/2018
19:05
£3.10 was resistance but now support imho.
wetdream
10/1/2018
12:33
Time for a top up on this overlooked stock.
volsung
14/12/2017
10:46
Pre-Close Trading Update Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, today announces an update on trading for the year ending 31 December 2017. The Group continues to make good progress and the Board expects revenue and profitability to be in line with current market expectations that include the positive impact from the recent Organogenesis licensing deal. Chris Meredith, Chief Executive Officer of AMS, said: "The Group continues to deliver strong organic growth supported by our Research and Development activities that provide both product innovation and intellectual property. AMS is well positioned to continue on its growth trajectory." The Group expects to publish its Preliminary Results for the year to 31 December 2017 in March 2018. Adoption of IFRS 15 IFRS 15 (Revenue from Contracts with Customers) becomes mandatory for AMS from 1 January 2018. The main effect for AMS will be to recognise the fees received from royalty payments and from regulatory agreements as Revenue rather than as Other Income. It will have no impact on profit or cash flow. The Group however has chosen to adopt IFRS 15 early and will be reporting its results for 2017 in line with its requirements. -End -
grabster
04/12/2017
09:54
ams,should find a use for nanene- see VRS
p@
20/11/2017
09:44
Could be the start of the next leg up. I've bought a few this am on that hunch
volsung
14/11/2017
13:15
No buyers in sight so share price drops on pitiful volume.
wetdream
10/11/2017
10:35
Markets very nervous imho.
wetdream
05/11/2017
10:41
Next trading update should be mid December.
potty punter
30/10/2017
15:09
Yes indeed `malcontent` highest ever share price today. Where to now, are we a target for the big boys?
dealit
30/10/2017
14:09
this one is out of the traps again and at a gallop what a stock
malcontent
27/10/2017
11:09
SP holding up well, given volume of sells-and it's a Friday.....
wetdream
27/10/2017
11:00
http://www.organogenesis.com/news/press-announcements.html
mirandaj
26/10/2017
22:51
Cgequityinvest, Couldn't agree more. It's the US link up that's more important (ok, the money's important too, but AMS is pretty cash-rich already). Traditionally, US cos will do their best to link up with other US cos first. It's a feather in AMS's cap that they've made this move.
wetdream
26/10/2017
16:34
Ok, thanks cge, makes sense..
ilovefrogs
26/10/2017
16:04
I think the upside comes from :- * the income is a royalty stream so it should fall largely through to the bottom line. i.e. i would expect the margin to be very high. Based on brokers expectations of £18.1m net profit for y/e Dec, the payment of $2.5m (say £1.9m equiv) could increase eps by nearly 10% (assuming minimal costs to be offset). This equates closely with the circa 9% price increase today. * strategically its another key step in the US and will help further establish their presence over there. The US company looks a bit small to be a potential purchaser of AMS - its not publically quoted at present. will be interesting to see what revised forecasts emerge from the brokers over the next week or so. Still at a high p/e multiple but this is a quality business with a long, strong track record of growth and cash generation.
cgequityinvest
26/10/2017
14:13
Anyone know just how significant the RNS is. Doesn't give any indications of revenue above agreed minimums (which are small in the scheme of things)
ilovefrogs
26/10/2017
12:47
http://www.cardinalhealth.com/content/dam/corp/web/documents/brochure/cardinal-health-liquiband-octyl-topical-skin-adhesive-brochure.pdf http://www.cardinalhealth.com/en/product-solutions/medical/skin-and-wound-management/surgical-wound-closure/liquiband--octyl-topical-skin-adhesive.html For interest
mirandaj
26/10/2017
11:31
S/P moved North on the announcement today.
dealit
19/9/2017
10:38
Steady buyback of own shares, and organic growth through own product development . Markets are frothy , takeovers are risky
norbus
18/9/2017
14:00
It will be interesting to see what the company decide to do with all their(our) cash- special dividend would be most welcome....
malcontent
Chat Pages: 281  280  279  278  277  276  275  274  273  272  271  270  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180122 16:32:05